The University of Southern Denmark has conducted a hepatitis B vaccine study involving approximately 14,000 infants in Africa, with half receiving the vaccine shortly after birth while the other half were vaccinated six weeks later. The study aims to compare the outcomes over five years. However, the World Health Organization has criticized the trial as unethical, citing the already proven effectiveness of the vaccine used in more than 115 countries for over 30 years, questioning the need for delayed vaccination in such a vulnerable population.

The WHO report highlighted that hepatitis B caused around 1.1 million deaths worldwide in 2022, with particularly high rates of infection reported in Guinea-Bissau, where 12% of adults are currently infected. The concerns are particularly poignant considering the history of medical research in Africa that has previously led to tragic outcomes, raising alarms about the implications of such studies that could potentially inflict irreversible harm on participants.

With nearly half of the infants receiving their vaccinations late, critics warn that the experiment lacks justification, emphasizing ethical standards in medical research and the importance of prioritizing the health of vulnerable populations such as infants. The ongoing debate around this study underscores the necessity for stringent ethical guidelines in clinical trials, especially in regions with a high burden of disease and susceptible demographic groups.